Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment

M. Moretti (Pisa (PI), Italy), E. Pozzi (Paderno, Milano,, Italy)

Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Session: Clinical studies of COPD: combination inhalers and much more
Session type: E-poster session
Number: 983
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Moretti (Pisa (PI), Italy), E. Pozzi (Paderno, Milano,, Italy). Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment. 983

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 252s
Year: 2004

Efficacy and safety of various antimicrobial regimens in the treatment of acute exacerbations of chronic bronchitis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007


N-acetylcysteine for the treatment of acute exacerbations of COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 374s
Year: 2002

Efficacy and safety of intravenous montelukast in patients with acute exacerbations of bronchial asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 351s
Year: 2003

Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Clinical efficacy of nebulised budesonide in acute exacerbation of COPD
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010

Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001

Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD
Source: Annual Congress 2013 –COPD treatment
Year: 2013


Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma
Source: Annual Congress 2007 - New drugs for asthma
Year: 2007




Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015

Long-term azithromycin therapy in severe COPD with repeated exacerbations
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010


Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014

Roflumilast in the treatment of COPD: A pooled safety analysis
Source: Annual Congress 2010 - COPD: management
Year: 2010

Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


An analysis of non-effective empiric antibacterial therapy in COPD acute exacerbation
Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections
Year: 2007